First-in-Human Phase I Study of Fisogatinib (BLU-554)...

Cancer Discovery 2019 / 12 Vol. 9; Iss. 12

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Kim, Richard D., Sarker, Debashis, Meyer, Tim, Yau, Thomas, Macarulla, Teresa, Park, Joong-Won, Choo, Su Pin, Hollebecque, Antoine, Sung, Max W., Lim, Ho-Yeong, Mazzaferro, Vincenzo, Trojan, Joerg, Zh
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
9
Journal:
Cancer Discovery
DOI:
10.1158/2159-8290.CD-19-0555
Date:
December, 2019
File:
PDF, 13.65 MB
2019
Conversion to is in progress
Conversion to is failed